Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16373491 | 0.87 | FYN (0.46) | FYNEGFRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16373693 | 0.87 | FYN (0.46) | FYNEGFRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16332162 | 0.83 | FYN (0.42) | FYNKDM1ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16332455 | 0.83 | ABCG2 (0.53) | FYNEGFRABCG2KDM1ACYP1A2 | |
| SCHEMBL16331336 | 0.82 | FYN (0.42) | FYNBRAFJAK2FLT3MAP4K4 | |
| SCHEMBL16332258 | 0.82 | FYN (0.51) | FYNCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16332149 | 0.82 | FYN (0.42) | FYNEGFRCTSC | |
| SCHEMBL16331623 | 0.82 | FYN (0.51) | FYNEGFRABCG2RAF1BRAF | |
| SCHEMBL16332075 | 0.82 | FYN (0.40) | FYNCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16332052 | 0.80 | FYN (0.39) | FYNEGFRABCG2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| EP-2818472-A1 | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2818472-A1 | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | FYN 574/4885EGFR 1348/4885ABCG2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.